Turning Point Brands, Inc. registered common stock, preferred stock, depositary shares, warrants, units and debt securities for future shelf offerings, with specific terms set in later supplements. Proceeds are generally earmarked for general corporate purposes.
TPB · Turning Point Brands, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Turning Point Brands reported nine-month net sales of $418,334 thousand, up from $342,049 thousand, while third-quarter net income attributable to the company fell to $3,930 thousand from $21,080 thousand. It also received $17.8 million in tariff refunds in June 2026.
Turning Point Brands reported third-quarter net sales up 27% year-over-year to $151 million, led by Modern Oral, and maintained full-year Adjusted EBITDA guidance of $70 to $80 million.
Turning Point Brands reported Q3 2026 Modern Oral gross sales up 114.2% to $93.9 million. Consolidated net sales rose 27.0% to $151.1 million, while net income fell 81.4% to $3.9 million.
Turning Point Brands appointed David E. Glazek CEO effective October 1, 2026, succeeding Graham Purdy, who resigned for personal reasons without disagreement. 2026 EBITDA guidance tightened to $70 million to $80 million from $70 million to $90 million.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 9, 2026TL;DR. Modern Oral drove triple-digit growth, consolidated sales and gross profit increased, Stoker’s grew 52.0%, chain distribution is expanding, and full-year guidance was reaffirmed. Profitability and adjusted diluted EPS declined as SG&A rose, Zig-Zag sales and Stoker’s gross margin declined, and fourth-quarter PMTA spending and manufacturing timing remain risks.
- + Modern Oral gross sales increased 114.2% to $93.9 million and net sales increased 102.9% to $74.4 million in Q3 2026. new
- + Stoker’s segment net sales increased 52.0% to $113.8 million, driven by triple-digit Modern Oral growth. new
- + The company reaffirmed its 2026 Modern Oral sales and Adjusted EBITDA guidance. new
- + Management is on track to increase the chain store count by more than 70% during 2026. new
- − Consolidated SG&A expenses increased 69.1% to $75.3 million, including Modern Oral sales and marketing investments and higher outbound freight costs. new
- − Zig-Zag segment net sales decreased 15.5% to $37.3 million and gross profit decreased 15.6% to $21.4 million. new
- − Stoker’s gross margin declined to 56.0% from 60.2%, primarily because of the product mix shift toward Modern Oral. new
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Mentioned in fund letters
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted Diluted EPS non-GAAP | $0.41 | Q3 2026 | — |
|
|
|||
| Adjusted EBITDA non-GAAP | $18.4M | Q3 2026 | — |
|
|
|||
| Adjusted Net Income non-GAAP | 8.31M | Three Months Ended September 30, 2026 | — |
|
|
|||
| Availability on asset backed revolving credit facility | $71.5M | End of Q3 2026 | — |
| Average price per share of repurchased shares | $59.82 | Q3 2026 | — |
| EBITDA non-GAAP | 12.51M | Three Months Ended September 30, 2026 | — |
|
|
|||
| Modern Oral Gross Sales | $93.9M | Q3 2026 | — |
| Modern Oral Net Sales | $74.4M | Q3 2026 | — |
|
|
|||
| Modern Oral share of total company Net Sales | 49.2% | Q3 2026 | — |
|
|
|||
| Net debt | $48.7M | As of September 30, 2026 | — |
| Shares repurchased | 167,161 | Q3 2026 | — |
| Total liquidity | $322.8M | End of Q3 2026 | — |
| Adjusted gross profit non-GAAP | $81.5M | Q2 2026 | — |
| Average selling price per share under the ATM Program | $90.3 | the quarter ended June 30, 2026 filing | — |
| Gross proceeds under the ATM Program | $60.8M | the quarter ended June 30, 2026 filing | — |
| Modern Oral Gross Revenue | $87M | Q2 2026 | — |
| Shares sold under the ATM Program | 672,884 | the quarter ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Tobacco — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TPB
this stock
Turning Point Brands, Inc.
|
$944.98M | -56.2% | +28.4% | 15.3 | 16.7% |
|
PM
Philip Morris International Inc.
|
$300.40B | +20.2% | +7.3% | 28.2 | 1.0% |
|
MO
Altria Group, Inc.
|
$126.85B | +32.3% | -3.1% | 15.7 | 2.4% |
|
BTI
British American Tobacco p.l.c.
|
$125.62B | +3.3% | — | — | 0.3% |
|
RLX
RLX Technology Inc.
|
$1.78B | -37.3% | +50.3% | — | 0.7% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 16, 2026
- This year
- 12
Turning Point Brands, Inc. registered common stock, preferred stock, depositary shares, warrants, units and debt securities for future shelf offerings, with specific terms set in later supplements. Proceeds are generally earmarked for general corporate purposes.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TPB | -19.2% | -26.4% | -44.0% | -29.4% | -56.2% |
| SPY | -3.9% | -5.6% | -3.5% | -3.4% | +7.1% |
| vs SPY | -15.3% | -20.9% | -40.6% | -26.0% | -63.2% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.